|
|
|
|
|
|
Scientific Advisory Boards
Cardax Pharmaceuticals has put together two world-class and interactive Scientific Advisory Boards with members in several relevant areas, including:
BREAKING NEWS:
The American Journal of Cardiology publishes: "Oxidative Stress and Heart Disease", a journal supplement based on presentations from the first Cardax Cardiovascular Scientific Advisory Board meeting.
Am J Cardiol 2008; 101 (10, Suppl 1)
Cardiovascular SAB - Chemistry/Molecular Biology
| Hansgeorg Ernst, Ph.D.
Senior Scientist responsible for the synthesis and process development of carotenoids (including
astaxanthin) at BASF AG, the world’s largest chemical company.
|
|
|
R. Preston Mason, Ph.D.
Professor and senior research staff scientist at Brigham & Women's Hospital, Harvard Medical School.
Focuses on vascular biology, endothelial function and LDL-oxidation. Most recent work specifically
addresses the issue of what may explain the increasing rate of atherosclerotic CAD events in patients
taking certain Cox-2 inhibitors.
|
|
|
Marc S. Penn, M.D., Ph.D.
Medical Director of the Bakken Heart-Brain Institute and the Coronary Intensive Care Unit at the
Cleveland Clinic. Also, Director of Cleveland Clinic’s Experimental Cardiology Laboratory, which is
dedicated to the discovery and implementation of novel drug and gene therapies.
|
|
|
Gilbert M. Rishton, Ph.D.
Founder and Director of the non-profit, Channel Islands Alzheimer’s Institute. Led medicinal
chemistry efforts in pharma for over fifteen years, most recently at Amgen.
|
|
|
Sotirios (Sam) Tsimikas, M.D.
Associate Professor of Medicine and Director of Vascular Medicine at the University of California,
San Diego. Developing plasma markers to measure oxidized LDL and its relationship to the
progression of atherosclerosis.
|
|
|
|
|
|
